Products
Online Inquiry
Mirabegron
Cat. No.:
0225LY-1161
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Mirabegron is a beta-3 adrenergic agonist specifically utilized in the clinical treatment of overactive bladder syndrome.
Synonym:
YM178; 223673-61-8; Myrbetriq; Betanis; Betmiga; YM-178; Mirabegron (YM178); YM 178; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide; 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide; 2-(2-Aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide; 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
CAS No.:
223673-61-8
Compound CID:
9865528
Formula:
C21H24N4O2S
Formula Weight:
396.51
Specification
Targets&IC50:
β3-adrenoceptor: 22.4 nM(EC50)
Relative Density:
1.313 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Mirabegron can be used in urological research to study the relaxation of detrusor smooth muscle via beta-3 adrenoceptor activation.
Library Information
Target:
β3-Adrenergic receptor
Receptor:
GPCR
Pathways:
Neuronal signaling; GPCR/G protein signaling
Plate Number:
AOCL-15
Plate Location:
h8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
252.5 mg/mL; 636.81 mM
Ethanol Max Solubility:
8 mg/mL; 20.18 mM
